ACM-001.1 Investigated for Preserving Lean Body Mass During and After Semaglutide-Induced Weight Loss
Background
Obesity is a global health challenge, with effective treatments like semaglutide offering significant weight loss. While beneficial, substantial weight reduction often leads to a decrease in lean body mass (LBM), raising clinical concerns about muscle preservation and overall metabolic health. This LBM loss can impact strength, function, and long-term health outcomes. The current study aims to address this critical gap by exploring an intervention to maintain or increase LBM during and after semaglutide treatment.
Study Design
This two-part clinical study (PROACT 1 and PROACT 2) investigates the effect of ACM-001.1 ((S)-Pindolol Benzoate) on lean body mass (LBM) in obese patients. PROACT 1 evaluates LBM changes when ACM-001.1 is co-administered with semaglutide. PROACT 2 assesses LBM gain when patients continue ACM-001.1 after discontinuing semaglutide. The primary endpoint is the effect on LBM, aiming to determine if ACM-001.1 can mitigate muscle loss during semaglutide-induced weight reduction and promote muscle recovery.
Why It Matters
If successful, ACM-001.1 could significantly improve the quality of weight loss achieved with semaglutide, shifting the focus from mere weight reduction to optimized body composition. This would be a major step towards mitigating the clinically concerning loss of lean body mass often associated with rapid weight loss, potentially preserving strength, metabolic health, and overall functional capacity for individuals. For those using semaglutide, this research could lead to a future protocol where an adjunct therapy like ACM-001.1 is integrated to ensure healthier, more sustainable weight management outcomes.
semaglutide
obesity
lean-body-mass
weight-loss
muscle-preservation
clinical-trial